Campral

Campral, also known by the brand name Campral®, is a drug used for treating alcohol dependence.
Campral is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcoholism, possibly by blocking glutaminergic N-methyl-D-aspartate receptors, while gamma-aminobutyric acid type A receptors are activated. Reports indicate that acamprosate only works with a combination of attending support groups and abstinence from alcohol. Certain serious side effects include allergic reactions, irregular heartbeats, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Campral should not be taken by people with kidney problems or allergies to the drug.

Medicinal name:
  • Acamprosate calcium 333 MG Delayed Release Oral Tablet [Campral]

Campral - Pharmacology:

The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. in vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance.

Campral mini report

Campral NDA
NDA - A product marketed under an approved New Drug Application
Campral TABLET, DELAYED RELEASE
TABLET, DELAYED RELEASE
Campral HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Campral global name
acamprosate calcium
Start - Stop data
START DATA:
2005-Jan-11
Start - Stop data
STOP DATA
not occurred

Campral for patients

Physicians are advised to discuss the following issues with patients for whom they prescribe CAMPRAL.

Any psychoactive drug may impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that CAMPRAL therapy does not affect their ability to engage in such activities.

Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy.

Patients should be advised to notify their physician if they are breast-feeding.

Patients should be advised to continue CAMPRAL therapy as directed, even in the event of relapse and should be reminded to discuss any renewed drinking with their physician.

Patients should be advised that CAMPRAL has been shown to help maintain abstinence only when used as a part of a treatment program that includes counseling and support.

Campral Interactions

The concomitant intake of alcohol and Campral does not affect the pharmacokinetics of either alcohol or acamprosate.

Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate. Co-administration of naltrexone with Campral produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate. No adjustment of dosage is recommended in such patients.

The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Campral.

Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Campral concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications. Patients taking Campral concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.

Campral Contraindications

Campral is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components.

Campral is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min).

Manufacturers name:

  • Carilion Materials Management
  • Forest Laboratories, Inc

Generic name, Overdose, Half Life Campral, Food Interactions, Chemical, etc..

Campral see also FDA report


Chemical structure:
O O N S O O H H H H H H H H H H H C5H11NO4S 2D chemical structure C5H11NO4S SVG | 2D structure Acamprosate | S-Dioxymethionine | chemical names, chemical properties, classification C5H11NO4S